97 results
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
28 Mar 24
Current report (foreign)
1:21pm
The collaboration between InterSystems and IPA leverages the strengths of both platforms to offer several transformative benefits:
Precision and Depth in Data … , healthcare, integration and / or success of LENSai with Vector Search, or HYFT technologies, including their benefits, and statements relating to IPA's
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
20 Mar 24
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
12:02pm
that the expected healthcare benefits including lowering development timeliness, and costs and that development of targeted treatments will not be achieved
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:00am
is translated at the January 31, 2024 rate.
9.EMPLOYEE REMUNERATION
Expenses recognized for employee benefits for the three and nine months ended January … , salaries
Employee benefits
Payroll taxes
Severance
Share-based payments
10.RELATED PARTY TRANSACTIONS
Key management personnel are those persons having
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
7 Mar 24
Current report (foreign)
11:19am
of LENSai, LLMs, RAG, or HYFT technologies, including their benefits, and statements relating to IPA's expected increased revenue streams … not have the expected results, risks that the expected healthcare benefits including lowering development timeliness, and costs and that development
6-K
IPA
ImmunoPrecise Antibodies Ltd
7 Mar 24
Current report (foreign)
11:19am
, the life sciences, drug discovery and development, integration and / or success of LENSai, LLMs, RAG, or HYFT technologies, including their benefits … that the integration of IPA's LENSai platform with its HYFT technology may not have the expected results, risks that the expected healthcare benefits
6-K
EX-10.1
l5q0re4n3xtu62
23 Feb 24
Current report (foreign)
5:29pm
424B5
njbfwr9p76rce1jbg1m8
23 Feb 24
Prospectus supplement for primary offering
5:26pm
6-K/A
EX-99.2
v6p4vl
15 Feb 24
Current report (foreign) (amended)
3:12pm
6-K
EX-99.2
ensydrt5nfr2kz0ifkjz
14 Dec 23
Current report (foreign)
8:38am
424B5
aekyv35ec x7wp
7 Dec 23
Prospectus supplement for primary offering
4:53pm
6-K
EX-10.1
ns2i mukzd65yte
6 Dec 23
Current report (foreign)
5:19pm
424B5
rdrskys bfbn
5 Dec 23
Prospectus supplement for primary offering
4:02pm
6-K
EX-99.1
bmlbm y2az1i
20 Oct 23
Current report (foreign)
2:56pm
6-K
EX-99.1
5jjen2 rbgfnaoj
18 Sep 23
Statement of Executive Compensation
2:47pm
6-K
EX-99.2
3dezigxsx80 2p
14 Sep 23
Current report (foreign)
8:02am
6-K
EX-10.1
tlag2xz
15 Aug 23
Current report (foreign)
5:50pm
424B5
k7y7m f7b5cudr3
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
f061c9zuk
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-4.3
e4jjg qi1c
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
EX-99.1
2vbilyhpah8 33s4m4r
10 Jul 23
Annual report (Canada)
4:32pm